BTBD8 Inhibitors
BTBD8 inhibitors represent a class of chemical compounds thatdiminish the activity of BTBD8. PD 0332991, a selective CDK4/6 inhibitor, disrupts cell cycle progression, which could impair BTBD8's role if it is associated with cell cycle control mechanisms. Rapamycin, an mTOR inhibitor, hampers protein synthesis and cell growth signaling, similarly leading to a potential reduction in BTBD8 activity if it is a component of these pathways. Histone deacetylase inhibition by Trichostatin A could alter the acetylation status of histones or non-histone proteins, thereby affecting BTBD8 function if it is contingent on such epigenetic modifications. Proteasome inhibition by MG-132 can impact BTBD8 if it is part of the ubiquitin-proteasome system, leading to an accumulation of proteins that may indirectly inhibit its activity.
Further influencing the function of BTBD8 are inhibitors like LY 294002, which targets the PI3K/Akt pathway, potentially leading to a decrease in BTBD8 activity. Fluorouracil's action on thymidylate synthase and subsequent DNA damage might inhibit BTBD8 if it plays a role in DNA replication or the DNA damage response. Energy depletion within the cell, induced by WZB117's inhibition of glucose transport, could also diminish BTBD8 activity if it is energy-dependent. Inhibitors such as Brefeldin A, Cyclopamine, PD 98059, and U-73122 target various other pathways including protein trafficking, Hedgehog signaling, MAPK/ERK signaling, and PLC-dependent pathways, respectively, each potentially reducing BTBD8 activity by modulating the specific processes it may regulate. Mitomycin C's induction of DNA crosslinking could also lead to the inhibition of BTBD8 through DNA damage-induced pathways if BTBD8 is implicated in the cellular response to genotoxic stress. Collectively, these inhibitors demonstrate the complex network of cellular pathways that BTBD8 may interact with and how their perturbation can result in the reduced functional activity of BTBD8.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD 0332991 is a CDK4/6 inhibitor that impedes the cell cycle progression. BTBD8 interacts with certain proteins that are regulated during the cell cycle. Inhibition of CDK4/6 may disrupt BTBD8's role in the cell cycle regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts protein synthesis and cell growth signalling pathways. Inhibition of mTOR signalling could decrease the functional activity of BTBD8 if it is involved in these growth regulatory pathways. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that modulates chromatin structure and gene expression. If BTBD8 function is contingent on a specific acetylation state of histones or non-histone proteins, Trichostatin A could diminish its activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. If BTBD8 is involved in the proteasomal pathway, inhibition of proteasome activity could lead to altered BTBD8 function by protein accumulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor that hampers the PI3K/Akt pathway. If BTBD8 is part of or regulated by this pathway, its inhibition could lead to decreased BTBD8 activity through downstream effects. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil inhibits thymidylate synthase, leading to DNA damage and affecting DNA replication. BTBD8 may be involved in the DNA damage response or replication; thus, its activity could be indirectly inhibited by such DNA damage. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
WZB117 inhibits glucose transport, which could lead to energy depletion within the cell. If BTBD8 activity is energy-dependent, this inhibition could result in diminished BTBD8 function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts protein transport by inhibiting the ADP-ribosylation factor. If BTBD8 has a role in protein trafficking, this inhibitor could disrupt its activity by altering intracellular transport mechanisms. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine inhibits the Hedgehog signaling pathway. If BTBD8 is involved in this pathway or its downstream effects, inhibition by cyclopamine could lead to decreased BTBD8 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an MEK inhibitor that could disrupt the MAPK/ERK pathway. If BTBD8's activity is influenced by this pathway, then inhibition of MEK could lead to its functional diminishment. | ||||||